Anavex Life Sciences Reports Positive Results in Alzheimer’s Disease Trial
Anavex Life Sciences has announced promising findings from a recent phase 2b/3 trial of its investigational
drug, blarcamesine (ANAVEX2-73), in patients with early Alzheimer’s disease.
The study, which enrolled 508 participants, demonstrated significant reductions
in amyloid-ß biomarkers and slowed neurodegeneration.
The trial was conducted across 52 medical centers in five countries, with participants
receiving either blarcamesine or a...